memory enhancement: consolidation, reconsolidation and ... · m. alberini1 and dillon y. chen2...
TRANSCRIPT
Memory enhancement: consolidation,reconsolidation and insulin-like growthfactor 2Cristina M. Alberini1 and Dillon Y. Chen2
1 Center for Neural Science, New York University, New York, NY 10003, USA2 Mount Sinai School of Medicine, New York, NY 10029, USA
Review
Life and societies would change significantly if memorycapacity or persistence in health and disease could beenhanced. It has been known for many years that mem-ory can be improved and strengthened. Substancesknown to enhance memory include hormones, neuro-transmitters, neuropeptides and metabolic substrates.Recently, attention has been given to identifying themolecular mechanisms and targets whereby memoryenhancement can be achieved. One approach wouldbe to target the physiological changes that are inducedby learning and naturally required for memory strength-ening via consolidation and reconsolidation. Here, wereview approaches that boost memories by targetingthe cAMP response element binding protein-CCAAT en-hancer binding protein (CREB-C/EBP) pathway and/orits recently identified target gene insulin-like growthfactor 2 (IGF2).
IntroductionThe continuing increase in life span is unfortunately asso-ciated with an increased prevalence of cognitive dysfunc-tions, including memory loss and diminished ability toform new long-term memories. Aging-related memory im-pairment is a common condition characterized by mildsymptoms of cognitive decline. The aged populationbecomes slower in processing, storing and recalling newinformation, and shows impairments in cognitive function-ing, including memory, concentration and organization. ‘Iforget names so easily now’ or ‘I forget where I put thingsall the time’ are common complaints of the aged. Moredramatic and devastating are the cognitive and memorylosses in neurodegenerative diseases, such as Alzheimer’sdisease (AD), in which the impairments interfere withnormal life functioning. The economic impact of AD inthe USA alone is estimated to be more than US$100 billionannually [1]. Thus, it is imperative to identify or developapproaches that can restore or prevent memory impair-ments. Furthermore, ethical debates aside, the possibilityof speeding normal learning and boosting memory reten-tion is appealing to the healthy population. Hence, identi-fying memory enhancers is of great importance andinterest.
Corresponding author: Alberini, C.M. ([email protected]).Keywords: cognitive enhancer; memory consolidation; reconsolidation; growth factor.
274 0166-2236/$ – see front matter � 2012 Elsevier Ltd. All rights re
Numerous studies have indicated that memory can beenhanced with many types of strategy or drug that caneither boost the baseline of the biological systems ormodulate memory strengthening or retrieval. These drugsmodulate neurotransmission, neurotransmitter recep-tors, neuropeptide [2–4], stress and related hormones[5,6] and metabolism [7,8]. The literature on this topicand the list of effective drugs is vast. Here, we focus ourdiscussions on an ensemble of mechanisms that can betargeted to boost memories because they underlie thememory processes known as consolidation and reconsoli-dation. Indeed, one approach that can be employed tosearch for mechanisms and targets of memory enhance-ment is to identify and exploit the biological mechanismsby which learned information transforms into long-lastingmemory. Newly learned information becomes a long-termmemory through a process known as consolidation. Thisprocess converts the new labile memory trace into a stron-ger one that is resilient to disruption [9]. Consolidationrequires an initial phase of de novo gene expression that inanimal models of temporal lobe-dependent memoriestakes place over the first 24 h after training; its interrup-tion results in memory loss [10,11]. Moreover, once stableand resilient to disruption, memories can again becomelabile and sensitive to interference if they are reactivatedby, for example, recalling the memory. Memories thenregain their resilience to interference by undergoing aprocess known as reconsolidation [12–15]. In several typesof memory, reconsolidation has been found to be tempo-rally limited. In fact, in rodents, only young memories(weeks-old), not old (months-old) ones are lost after am-nesic agents are given together with memory reactivation[16–20]. It has been proposed that reconsolidation is aphase of lingering consolidation that in rodents can last forweeks [15,21]. If memory is retrieved during this sensitivephase, it undergoes reconsolidation to strengthen thememory itself, indicating that an important function ofthe post-retrieval reconsolidation process is to promotememory strengthening and persistence [15,22]. Thus, inprinciple, a strategy that potentiates either the initialconsolidation or the reconsolidation phases may be suc-cessfully exploited as an effective cognitive enhancer. Inagreement with this hypothesis, various gene mutationstargeting the pathways known to be involved in long-term plasticity or memory formation result in memory
served. doi:10.1016/j.tins.2011.12.007 Trends in Neurosciences, May 2012, Vol. 35, No. 5
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
enhancement. Excellent reviews have summarized anddiscussed these mutants [23,24].
In this review, we discuss the hypothesis that memorycan be enhanced by targeting a variety of steps of thecAMP-CREB-C/EBP-dependent gene cascade, which hasbeen shown to be required for memory consolidation innumerous species [25]. After a brief summary of currentknowledge, we expand on the effect of a target gene, IGF2,(also known as IGFII), which is regulated by the CREB-C/EBP pathway [26]. We also discuss memory enhancementin reconsolidation and relative temporal constraints andconclude with some unresolved questions about memoryenhancement and its potential clinical applications.
Promoting memory enhancement by targeting thecAMP-CREB-C/EBP pathwayStudies of the molecular bases of long-term memory for-mation started with the findings in simple invertebratesthat cAMP and the induction of CREB- and C/EBP-depen-dent gene expression have a key function in synapticplasticity and memory formation [27–29], particularlyduring the temporal window of consolidation, when mem-ory is still labile [9,30,31]. Specifically, in invertebrates,including Aplysia californica and Drosophila melanoga-ster, the molecular disruption of CREB or C/EBP isoformsleads to memory impairment [25]. Similarly, molecularand genetic disruptions of either CREB or C/EBP isoformsin rodents impair different types of long-term memory,including spatial, contextual, appetitive and aversive,leading to the conclusion that the cAMP-CREB-C/EBPpathway has an evolutionarily conserved, fundamentalrole in long-term memory formation [25,32–34]. Someauthors have found that the essential function of CREBin memory formation may be overcome by genetic back-grounds and that CREB-independent forms of long-termplasticity and memory exist [35]. Despite the fact thatsome form of memory and/or long-term potentiation(LTP) may indeed be CREB independent, these contrast-ing effects may be due to the result of protein compensationof the transgene that can overcome the requirement forCREB. Hence, in summary, numerous studies across spe-cies, brain regions and types of learning paradigm indicatethat CREB is critical for memory formation. Despite thepossibility that memory consolidation may also be en-hanced independently of the CREB pathway, in this re-view, we focus on discussing nodes of the CREB-C/EBPpathway that represent important targets for promotingmemory enhancement and persistence.
Several intracellular signaling pathways have beenshown to activate the CREB-C/EBP cascade [25](Figure 1), which include important targets for both mem-ory disruption and strengthening. Selective modulation ofspecific components of this pathway may lead to the en-hancement of memories and, furthermore, make themmore persistent. Indeed, studies have demonstrated thatthis is the case.
The expression of an activated form of CREB in bothDrosophila melanogaster and neuronal cultures of Aplysiacalifornica was found to lead to long-term memory and/orplasticity from learning or stimulation paradigms thatevoke only short-term memory or plasticity [28,36] (but
see [37]). Similarly, overexpression of C/EBP in Aplysianeurons converted short-term plasticity into long-termplasticity [38]. These findings were the first evidence that,if the molecular cascade involved in long-term plasticityand memory formation is overstimulated, memory reten-tion can be enhanced or made more persistent.
Similar results were found in mammalian systems.Overexpression of a neuronal-specific adenylyl cyclase 1(AC1), an enzyme that catalyzes the synthesis of cAMP, inthe forebrain of mice, resulted in enhanced object recogni-tion and contextual fear-conditioning memories [39]. Injec-tions of a protein kinase A (PKA) activator, Sp-cAMPs, intothe amygdala enhanced reward-related learning in a dose-dependent manner [40]. Furthermore, rolipram, an inhib-itor of the phosphodiesterase 4 (PDE4) family of enzymes,which catalyze cAMP hydrolysis and thereby increasecAMP concentrations and CREB phosphorylation, signifi-cantly enhanced memory retention in rodent contextualfear conditioning [41], object recognition [42] and severalspatial tasks [43]. In agreement with these results, recentstudies have shown that both PDE4 subtype D (PDE4D)-deficient mice and mice in which PDE4D in the dorsalhippocampus was knocked down by lentiviral vectors, haveenhanced spatial and object recognition memories [44].Inhibitors of other PDEs, for example, the selectivePDE5 inhibitors sildenafil, zaprinast and vardenafil, whichcan lead to an increase in CREB phosphorylation, havealso shown enhancing effects in spatial object recognitionand active avoidance memories in rodents [45,46], al-though others have reported contrasting findings [47].
Memory-enhancing effects have also been found bydirectly increasing the expression of CREB. Viral vector-mediated overexpression of CREB in the rat amygdala ormouse hippocampus enhanced cued and contextual fearconditioning, respectively [48,49]. Transgenic overexpres-sion of dominant active forms of CREB in the forebrainresulted in enhanced memory retention in a variety oftasks, including fear conditioning, social recognition, theMorris water maze and passive avoidance [50].
Boosting CREB-dependent transcription activity is likelyto promote memory enhancement by targeting many mech-anistic levels. For example, CREB regulates the transcrip-tion of proteins that are necessary for the stabilization ofmemory after learning. Thus, enhancing CREB activity mayaugment the levels of these critical proteins, resulting instronger memories. A series of elegant studies has increasedthe understanding of how CREB regulates memory forma-tion, thereby mediating memory retention. In the lateralamygdala, neurons with viral-mediated overexpression ofCREB are more likely to be active after memory retrievalthan are their neighboring neurons, and selective ablation ofthese CREB-overexpressing neurons leads to memory im-pairment [51,52], suggesting that auditory fear conditioningcan recruit CREB-expressing neurons in the lateral amyg-dala to establish fear memory formation. Furthermore,viral-mediated overexpression of CREB in the amygdalaenhances synaptic transmission and increases neuronalexcitability [53]. Similar increases in neuronal excitabilityare seen in the dorsal hippocampus of transgenic miceexpressing a constitutively active form of CREB [54], lead-ing to the conclusion that memory enhancement correlates
275
IGF-2
IGF-2
IGF-2
C/EBP
Neurotransmitters
Growth factors
Glutamate/Depolarization
ATP
AC
cAMP PDE
PI3K
RTK
NMDARVSCC
PKA
Akt p70S6K RSK2 MSK
Ras/Raf/MEK/MAPK
IEGs
Ca2+
CREB
RelaxedDNA
CondensedDNA
HDAC
HAT
C/EBP
C/EBP
CREBP CBP
TRENDS in Neurosciences
Figure 1. Schematic representation of the cAMP response element binding protein (CREB)-CCAAT enhancer binding protein (C/EBP) pathway activated during memory
formation. Neurotransmitters, growth factors and membrane depolarization are examples of the stimuli that activate intracellular signal transduction pathways that can
lead to the activation of the CREB-dependent pathway. Growth factors signal via receptor tyrosine kinase (RTK), which upon ligand binding and dimerization, induces
activation of two pathways: the Ras/Raf/mitogen-activated protein kinase (MAPK)/MAP kinase kinase (MEK) and the phosphatidylinositol 3-kinase (PI3K)-dependent
pathways. Activations of these pathways recruit additional protein kinases, including p90 ribosomal S6 kinase (RSK2) and mitogen- and stress-activated protein kinase
(MSK) for the MAPK-dependent pathway and Akt and p70S6 kinase(p70S6K) for the PI3K-dependent pathway to catalyze phosphorylation of CREB (pCREB) in its Ser-133
residue, which is an important step for its activation [25]. CREB phosphorylation can also be achieved by many neurotransmitters binding to their receptors. Via these
receptors, neurotransmitters can couple cAMP by regulating adenylyl cyclase (AC) activity. cAMP recruits protein kinase A (PKA) as the main kinase for CREB
phosphorylation. Phosphodiesterase (PDE) can catalyze the hydrolysis of cAMP and inhibit its signaling. Additionally, increases in intracellular Ca2+ influx through voltage-
or ligand-gated cation channels, such as voltage-sensitive calcium channels (VSCCs) or NMDA receptors (NMDARs), can also lead to CREB phosphorylation via different
calcium-dependent protein kinases [25]. Once phosphorylated, CREB recruits its transcription coactivator CREB-binding protein (CBP) to promote transcription [62]. The
functional activation of CREB leads to the expression of target genes, among which are immediate early genes (IEGs), such as the transcription factor C/EBP [27,108], which,
in turn, regulates the expression of late response genes, including insulin-like growth factor 2 (IGF2) [26]. Transcriptional regulation is further regulated by the chromatin
state. In general, histone acetyl transferases (HATs) acetylate histone tails and promote a relaxed chromatin state and transcription. Histone deacetylases (HDACs), by
contrast, de-acetylate histones and promote a condensed chromatin state and gene silencing [61].
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
with increased neuronal excitability that is mediated, atleast in part, by increased CREB expression and/or itsfunctions.
Furthermore, activation of the CREB-C/EBP cascade isregulated by inhibitory constraints [55–58], the removal ofwhich results in stronger or more persistent memories. Forexample, mutant mice with reduced expression of thegeneral control non-repressed 2 (GCN2) kinase, an eukary-otic initiation factor 2 a (eIF2a) kinase, have suppressedexpression of activating transcription factor 4 (ATF4)mRNA, a repressor of CREB-mediated gene expression,and display enhanced spatial memory, as assessed in theMorris water maze [59]. Likewise, mutant mice with re-duced phosphorylation of eIF2a exhibit enhanced memoryin a variety of tasks [60]. Similarly, transgenic mice withforebrain expression of a general dominant negative inhib-itor of the C/EBP/ATF family (EGFP-AZIP) have enhancedspatial memory retention. EGFP-AZIP expression presum-ably relieves the inhibitory regulators and results in alower threshold for LTP induction as well as increased
276
spatial memory retention [57]. In summary, any molecularstep that regulates the induction of the CREB- and/or C/EBP-dependent gene expression may, in principle, be agood target for promoting memory enhancement.
As with all transcription factors, CREB and C/EBP func-tions on gene expression are controlled by the state andregulation of chromatin. Chromatin modification can mod-ulate the transcription necessary for memory formation byregulating access of transcriptional regulatory proteins toDNA. For example, histone acetylation is a chromatin mod-ification that regulates DNA–histone interactions via twoopposing classes of enzyme: histone acetyltransferases(HATs), which acetylate histone tails and promote tran-scription, and histone deacetylases (HDACs), which de-acetylate histones and promote genes silencing [61]. Oneimportant function of CREB is to recruit CREB-bindingprotein (CBP), a cofactor with intrinsic histone acetyl trans-ferase activity, which results in increased gene transcription[62]. Genetic mutations in CBP are associated with Rubin-stein-Taybi syndrome, which is characterized by facial
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
abnormalities, broad thumbs and mental retardation [63].Mutant mice lacking one functional copy of CBP exhibitimpaired long-term inhibitory avoidance and contextualfear-conditioning memories [64]. More specifically, trans-genic mice with a functional loss of the HAT activity of CBPhave impaired long-term memory formation [65], whereasinjections of HDAC inhibitors, which would compensate fordeficits in CBP activity in CBP-mutant mice, rescue thememory impairment [65,66] Similarly, PDE4 inhibitors,which enhance CREB signaling, also dose dependentlyrescue the long-term memory defects in CBP mutants[67]. These studies suggest that modulating CREB-depen-dent signaling or the state of chromatin via HDAC inhibitorsare potential therapeutic options for cognitive disordersassociated with CBP dysfunction. In agreement with thishypothesis, in wild-type mice, HDAC inhibitors have beenfound to enhance long-term memory in a variety of tasks,including contextual fear conditioning [68], water maze [69],fear-potentiated startle [70], extinction of fear memory [71]and novel object recognition [72]. Several extensive reviewshave been published on HDAC inhibitors and their potentialapplications to treat cognitive disorders [73–75].
One step downstream of the activation of CREBs and C/EBPs is regulation of the expression of their target genes.Some of these target genes may include secreted factors ormembrane receptors that can be more easily targeted bypharmacological approaches. One of these genes, IGF2,was recently identified [26].
Proliferation Surviv
IGF-1Insulin
IGF-1R
IR
MEK
Raf
Ras
MAPK
P
SHC
S6K
SosGrb2
PP
PP
PI3KIRS
PP
P P P P
P PP
Figure 2. The insulin-like growth factor (IGF)-related system components. The IGF-relate
circulation are regulated by IGF binding proteins (BPs). There are multiple receptor conf
Two isoforms of IR, IR-A and IR-B, are found in the brain [109]. For simplicity, only sign
phosphorylation of adaptor proteins belonging to the IR substrate (IRS) family or Src hom
SHC leads to activation of Raf/Ras/mitogen-activated protein kinase (MAPK)/MAP
Phosphorylation of Akt leads to subsequent activation of mammalian target of rapam
(S6K). Activation of these pathways leads to enhanced proliferation, survival and metas
the highest affinity to IGF-2R. IGF-2R is structurally distinct from IR and IGF-1R, and is no
mediated lysosomal degradation as well as effecting signal transduction [85] (Fi
phosphoinositide-dependent kinase-1; PIP3, phosphatidylinositol (3,4,5)-trisphosphate.
IGF2, a C/EBP target gene required for memoryconsolidation, promotes memory enhancementIGF2 has been recently identified as a target gene of C/EBPb during memory consolidation in rats [26]. IGF-2 is amitogenic polypeptide that is structurally similar to insu-lin and IGF-1. Insulin, IGFs and their respective receptors,together with IGF-binding proteins (IGFBP), constitutethe IGF-related system (Figure 2). This protein systemis important for normal somatic growth and development,tissue repair and regeneration [76]. Compared with theother family members, IGF-2 is more abundantlyexpressed in the adult brain and is found in regions thatare critically involved in memory consolidation, such as thehippocampus and cortex [77]. The mechanism of action ofIGF-2 is not clear and may be multifaceted [78]. Thehighest affinity of IGF-2 is for IGF-2 receptor (IGF-2R).Beside IGF-2, IGF-2R binds a large number of ligands,including lysosomal enzymes, transforming growth factor-b (TGF-b), granzyme B, plasminogen, glycosylated leuke-mia inhibitory factor and retinoids [79]. Most IGF-2Rs, alsoknown as cation-independent mannose 6 phosphate recep-tors, are located intracellularly where they facilitate thetrafficking of lysosomal enzymes between the trans-Golginetwork, endosomes and lysosomes [79]. Cell-surface IGF-2Rs sequester circulating and local levels of IGF-2, therebyleading to IGF-2 degradation. IGF-2Rs can also mediatethe endocytosis of extracellular lysosomal enzymes [80].IGF-2 can also bind with lower affinity to IGF-1 receptors
al Metastasis
IGF-1
IGF-2
IGF-2
mTOR
IP3
Akt
eIF4E
PDKI
BPs
BPs
IGF-2R
IGF-2
P PNo tyrosine
kinase activity, targets IGF-2to lysosomal degradation
TRENDS in Neurosciences
d system comprises three ligands: insulin, IGF-1 and IGF-2. IGF-1 and IGF-2 levels in
ormations. Insulin and IGF-1 receptor (IR and IGF-1R) are tyrosine kinase receptors.
aling initiated by the activated IGF-1R is shown. Activation of IR or IGF-1R leads to
ology 2 domain-containing transforming protein (SHC) [110]. Activation of IRS and
kinase kinase (MEK) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways.
ycin (mTOR), eukaryotic translation initiation factor 4E (eIF4E) and p70S6 kinase
tasis in cancer cells [110]. IGF-2 binds IR-A [111], IGF-1R and IGF-2R [110], and with
t a receptor tyrosine kinase. Once IGF-2 binds, IGF-2R targets IGF-2 to endocytosis-
gure 4). Abbreviations: Grb2, growth factor receptor-bound protein 2; PDKI,
277
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
(IGF-1Rs), which results in the downstream activation oftypical tyrosine kinase-mediated growth pathways [78].
IGF-2 mRNA and protein levels were found to be upre-gulated in the rat hippocampus 20 h after inhibitoryavoidance training [26]. Inhibitory avoidance is a contex-tual fear conditioning-based task that requires an intacthippocampus and amygdala, and is used as a model oftemporal lobe-dependent memories. This training-depen-dent induction in the hippocampus was dependent on thebinding of C/EBPb to IGF-2 promoters [26], in agreementwith previous findings indicating that the IGF-2 promo-ters bear C/EBPb consensus sequences [81]. Furthermore,either antisense-mediated knockdown of IGF-2 in thedorsal hippocampus or injections of a function-neutraliz-ing anti-IGF-2R antibody significantly impaired long-term inhibitory avoidance memory, suggesting that thelearning-dependent increase in IGF-2 (via IGF-2R) isrequired for inhibitory avoidance memory consolidation
Training Test 1
0 h
24 h
(a)
Test
3 w
100
300
500
700
900
7 d
Test 2
24 h 7 d
Mea
n la
tenc
y (s
)
(
3 w
Test 1 Final test
100
300
500
700
900
NoR final test
Training Test1
0 h 24 h 48 h
Final test(c)
Mea
n la
tenc
y (s
) ***
(
*
******
*****
**
Figure 3. Insulin-like growth factor 2 (IGF-2) enhances fear as well as fear extinction mem
received bilateral intrahippocampal injections of IGF-1 (grey bars), IGF-2 (black bars), or veh
and 7 days (Test 2) after training. Rats that received IGF-2, compared with IGF-1 and ve
intrahippocampal injections of IGF-2 immediately after inhibitory avoidance training, com
with IGF-2 immediately after inhibitory avoidance training showed significantly higher me
solution showed significant memory retention decay [26]. (b) Rats underwent contextual/a
and freeze in subsequent exposure to the training context or to the tone in a different c
injections of IGF-2 (black bars) or vehicle (white bars; indicated by #). Rats that were injecte
when they were tested in the training context. By contrast, no effect was seen on the audito
injected with vehicle [26]. (c) Rats underwent inhibitory avoidance training and were
intrahippocampal injection of either IGF-2 (black bars) or IGF-1 (grey bars), whereas the oth
thereafter received similar bilateral intrahippocampal injections (indicated by #). All group
when given 24 h after training (NoR final test), but, if given in concert with memory retr
underwent contextual fear conditioning and context-dependent freezing was assessed 2
intervals consisting of re-exposure to the training context without footshock. Fear extinctio
the dorsal hippocampus immediately after each extinction trial (indicated by #) compared w
% freezing � s.e.m.; *P <0.05, **P <0.01, ***P <0.001. Adapted, with permission, from [
278
[26]. Conversely, injections of recombinant IGF-2 into thedorsal hippocampus immediately after training, but not24 h later, significantly and dose-dependently enhancedlong-term inhibitory avoidance and contextual fear mem-ory retention (Figure 3a,b), as well as preventing memoryloss (Figure 3a) [26]. In fact, rats given a single hippocam-pal injection of IGF-2 immediately after training still hadsignificant memory retention 3 weeks after training,whereas vehicle-injected control rats had largely forgotten(Figure 3a) [26]. Injections of IGF-2 into the amygdala hadno effect on memory retention, suggesting that the mech-anisms regulated by IGF-2 in memory enhancement tar-get selective regions, such as the hippocampus, but not theamygdala [26]. Furthermore, hippocampal injections ofIGF-2 have also been found to facilitate fear extinction inmice (Figure 3d) [82], confirming and extending the con-clusion that IGF-2 promotes memory enhancement. It willbe important to investigate other brain regions as targets
20
40
60
Per
cent
free
zing
20
40
60
80
Per
cent
free
zing
b) Context/Auditorytraining
Context test
0 h 24 h
Auditorytest
48 h
Per
cent
free
zing
20
40
60
30
50
70
10
01 2 3 4 5 6 7
Extinction trials (da ys)
d)
**
* *
*
Baseline Context test Auditory test
TRENDS in Neurosciences
IGF-2
Veh
Key:
Veh
IGF-2
IGF-1
ories. (a) Rats underwent inhibitory avoidance training, immediately after which they
icle solution (white bars; indicated by #). Memory retention was tested at 24 h (Test 1)
hicle solution, had significantly higher memory retention at both tests [26]. Similar
pared with vehicle solution, significantly prevented memory forgetting. Rats injected
mory retention at 3 weeks after training (Test), whereas the rats that received vehicle
uditory fear conditioning, in which they associate a context and a tone to a footshock
ontext. Immediately after conditioning, the rats received bilateral intrahippocampal
d with IGF-2, compared with vehicle solution, had a significantly higher freezing score
ry fear-conditioning test, as rats injected with IGF-2 had freezing scores similar to rats
divided into two groups. Twenty-four hours later, one group received a bilateral
er group underwent inhibitory avoidance memory retrieval (Test 1) and immediately
s were tested for memory retention 48 h after training (Final test). IGF-2 had no effect
ieval, compared with IGF-1, significantly enhanced memory retention [26]. (d) Mice
4 h later. Extinction of contextual fear was performed on consecutive days at 24-h
n was significantly enhanced in mice that received injections of IGF-2 (red circles) into
ith the vehicle-injected group (grey squares) [82]. Data are shown as mean latency or
26] (A–C) and [82] (D).
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
of IGF-2-mediated memory enhancement, such as thecortex. Such future studies will help to address questionsof region-specific mechanisms and/or selective effects onspecific memory systems in memory enhancement.
IGF-2 is an interesting candidate for potential clinicalapplications because it is a naturally produced growth factorthat readily crosses the blood–brain barrier. In the adult rat,IGF-2 mRNA can be found in the brain, heart, kidney,uterus and liver [83], and peripheral IGF-2 can be trans-ported into the brain via IGF-2Rs localized in brain capillar-ies [84]. The temporally limited effect of hippocampallyinjected IGF-2 that occurs from the time of training (i.e.<24 h) as well as that of the post-retrieval effect in young butnot old memories (discussed below) indicates that bothconsolidation and reconsolidation mechanisms can be tar-geted to produce memory enhancement. Mechanistically,IGF-2-dependent memory enhancement requires the func-tion of IGF-2R, but not IGF-1R [26]. IGF-2R, unlike insulin-and IGF-1R, is not a tyrosine kinase receptor [85]. Whereasinsulin and IGF-1R mediate growth and activate the ras/raf/mitogen-activated protein kinase (MAPK) and phosphati-dylinositol 3-kinase (PI3K)/Akt pathways (Figure 2), IGF-2R/mannose-6-phosphate receptor binds IGF-2 extracellu-larly and/or transports lysosomal acid hydrolase precursorsfrom the Golgi apparatus to the lysosome [79] (Figure 4).IGF-2Rs from both the cell surface and Golgi traffic to theearly endosome, where the relatively low pH environmentcauses the release of the IGF-2R cargo. The IGF-2Rs arerecycled back to the Golgi by the retromer complex. The
IGF-2RIGF-2
GSK3β
Arc
AMPAR
Degradation
Endocytosis
Late endosome
Early endosome
Lysosome
?
Golgi Acid hydrolase
TRENDS in Neurosciences
Figure 4. Insulin-like growth factor 2 receptor (IGF-2R)-dependent lysosomal
enzyme trafficking, signaling transduction and endocytosis. Intracellular or
extracellular lysosomal enzymes, such as acid hydrolase, are transported to late
endosomes by IGF-2R (also known as the mannose 6-phosphate receptor) [80].
Lysosomal enzymes dissociate from IGF-2R within the low-pH environment of late
endosomes and are subsequently delivered to lysosomes. IGF-2R is recycled either
to the Golgi or to the cell surface [79]. At the cell surface, IGF-2 binding to IGF-2R is
followed by endocytosis to form early endosomes. From the early endosomes,
IGF-2R dissociates from IGF-2: IGF-2R is recycled to cell surface, whereas IGF-2 is
targeted to late endosome for lysosomal degradation [79]. A recent study [26]
suggests that, in the hippocampus, learning leads to IGF-2 binding to cell-surface
IGF-2R, which results in glycogen synthase kinase 3b (GSK3b) activation and
activity-regulated cytoskeletal-associated protein (Arc) synthesis, both of which
have been implicated in regulating AMPA receptor (AMPAR) endocytosis [88,93].
Internalized AMPARs can either recycle to the cell surface or be targeted for
degradation [112]. IGF-2/IGF-2Rs could also directly regulate AMPAR endocytosis
independently of GSK3b and Arc.
cargo proteins are then trafficked to the lysosome via thelate endosome independently of the IGF-2Rs [79] (Figure 4).How these and potentially other functions of IGF-2Rs lead tomemory enhancement is currently unknown.
IGF-2-mediated memory enhancement also requires denovo protein synthesis. Although IGF2 is a target gene of C/EBPb, IGF-2-mediated memory enhancement does not de-pend on de novo C/EBPb synthesis and does not correlatewith increased levels of pCREB and C/EBPb [26]. Thissuggests that IGF-2 does not exert its effects by amplifyingthese transcriptional mechanisms, but rather by acting ontranslational and synaptic mechanisms. Interestingly, oneof the newly synthesized proteins required for IGF-2-medi-ated memory enhancement is activity-regulated cytoskele-tal-associated protein (Arc; also known as Arg 3.1) [26]; itsfunctions are needed for long-term plasticity and memoryformation. For example, Arc is required in the hippocampusand the amygdala for the consolidation of spatial memoryand cued-fear conditioning, respectively [86,87]. Studieshave suggested that Arc is critical for long-term plasticityand memory because, by interacting with the endocyticmachinery proteins endophilin and dynamin, it regulatesmembrane trafficking of AMPA receptors [88,89]. AMPAreceptor trafficking is critically involved in LTP, long-termdepression (LTD) and memory. It is thought that AMPAreceptor subunits are rapidly transported in and out ofsynapses to strengthen or weaken synaptic activity duringplasticity and learning [90,91]. In agreement with thishypothesis of a positive correlation between plasticity andmemory formation and increased trafficking of synapticAMPA receptors, IGF-2-mediated memory enhancementwas found to correlate with increased levels of synapticGluA1 AMPA receptor subunits [26].
Endocytosis is also regulated by glycogen synthasekinase 3b (GSK3b), a serine/threonine kinase that wasoriginally identified as a regulator of cell metabolism buthas since been implicated in various functions, includingproliferation, cell survival, neural development, and shap-ing nerve terminal development and function [92]. In fact,endocytosis was found to be dependent on the phosphory-lation of dynamin I (at the Ser 774 residue) by GSK3b [93].IGF-2-mediated memory enhancement correlates with theactivation of GSK3b and requires the activity of GSK3 [26],supporting the hypothesis that the memory-enhancingeffect critically targets functions of the endocytic pathway.Previous findings suggested a correlation between in-creased endocytosis and increased GSK3 activation andArc expression [88,93]. Such findings appear to contrastwith the finding that memory enhancement is accompa-nied by increased synaptic expression of certain receptorsubunits (e.g. GluA1) [26]. However, it is possible thatendocytosis of other receptors as well as restructuring ofsynapses are also critical for enhancing synaptic strength.Moreover, increased endocytosis may play an importantrole in homeostatic synaptic scaling, which may enhancethe system capacity. Future studies will hopefully extendcurrent knowledge regarding the role of endocytosis inmemory enhancement.
An intriguing property of IGF2 and IGF2R is that theyare both imprinted genes. Imprinted genes are expressedonly by one allele, either maternal or paternal, and this
279
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
pattern of expression is maintained epigenetically in al-most all tissues. How imprinted genes participate in be-havior is a topic of great interest and recent investigations[94–96].
Interestingly, insulin and other insulin regulatory pro-teins have been shown to promote memory enhancement inrodents as well as in humans [97–99]. However the mech-anisms by which this effect occurs seem to be different fromthat of IGF-2. Further studies are needed to better dissectthe mechanisms of these effects.
Targeting reconsolidation to enhance memoryWhy does memory become labile after retrieval and un-dergo reconsolidation? The biological purpose of reconso-lidation has been the topic of debates and investigationssince its rediscovery more than 10 years ago [13]. Onedebated issue in the reconsolidation field is its relationshipwith the role of the passage of time [100]. In inhibitoryavoidance conditioning, retrieval leads to protein synthe-sis-dependent reconsolidation only if the memory is lessthan 2 weeks old. By contrast, 2- or 4-week old memories donot become fragile after retrieval and, in fact, are resilientto protein synthesis inhibitor treatment administered ei-ther systemically or via intra-amygdala injections [18,101].Similarly, contextual fear conditioning becomes increas-ingly resistant to post-retrieval administration of proteinsynthesis inhibitors with time [19]. By contrast, 45 or 60day old auditory fear conditioning memories are still sus-ceptible to disruption by protein synthesis inhibition in theamygdala after retrieval, and no temporal gradient ofresilience has been described [102,103]. In inhibitoryavoidance conditioning, whereas hippocampal protein syn-thesis is required for the initial consolidation, it is dispens-able during reconsolidation, indicating that mechanisms inthe amygdala, but not the hippocampus, are critical formemory reconsolidation [104]. Hence, in inhibitory avoid-ance and, perhaps, other temporal-lobe-dependent memo-ries, hippocampal resistance to post-retrieval amnesictreatments may reflect the more cortically distributedrepresentation of the memory trace. By contrast, in pav-lovian fear conditioning, where the amygdala is necessarilyinvolved in the acquisition, storage and expression ofconditioned fear memory, reactivation of the very localizedtrace renders the memory labile. Whether this reflectsdifferences in molecular and/or circuit-based mechanismsremains to be understood.
One of the hypotheses proposed to explain the functionof reconsolidation is that memory reconsolidates to becomestronger and longer lasting [14]. Supporting this hypothe-sis, studies have demonstrated that a second training trialstrengthens a contextual fear memory [105]. This strength-ening requires the function of transcription factor earlygrowth response protein 1 (EGR-1; also known as Zif268) inthe hippocampus, which is also essential for the reconso-lidation, but not consolidation, of contextual fear condi-tioning [105]. Using inhibitory avoidance conditioning inrats, a recent study reported that unreinforced contextualreminders given when the memory is young, but not whenit is older, enhance memory retention and prevent for-getting [22]. Such findings indicate that reconsolidationdoes indeed promote memory enhancement. Targeting
280
reconsolidation mechanisms should therefore also provideopportunities to enhance memories.
Several studies have explored the possibility of enhanc-ing memory by targeting mechanisms activated duringreconsolidation. For example, activating PKA in the baso-lateral amygdala (BLA) with Sp-cAMP during reconsolida-tion leads to enhancement of rat auditory fear memoryretention; conversely, inhibiting PKA by administering 6-BNZ-cAMP to the same brain region immediately afterretrieval impairs reconsolidation and leads to amnesia[106]. Similarly, in the crab Chasmagnathus, blockingangiotensin II impairs reconsolidation, whereas exogenousadministration of recombinant angiotensin II enhances it[107].
IGF-2, which enhances inhibitory avoidance memorywhen administered to the hippocampus following training(Figure 3a), also significantly strengthens inhibitory avoid-ance memory when administered in the same brain regionafter memory retrieval (Figure 3c) [26]. The effect is re-trieval dependent and limited to the same exact temporalwindow during which inhibitory avoidance memory under-goes reconsolidation; that is, less than 2 weeks after train-ing. Hence, although the hippocampus is not a substratefor post-retrieval memory disruption after inhibitoryavoidance training, it is a substrate for post-retrievalmemory enhancement that occurs during the reconsolida-tion-sensitive temporal window. We conclude that, in me-dial temporal lobe-dependent fear memories, retrievalactivates the amygdala to control consolidation that ismediated by hippocampal mechanisms, leading to subse-quent strengthening and cortical redistribution of thetrace. These mechanisms can be targeted to promote mem-ory enhancement. Thus, to effectively target mechanismsof consolidation or reconsolidation for memory enhance-ment it is important to keep in mind that there aretemporal constraints. Hence, an enhancer that targetsthe hippocampal CREB-C/EBP-dependent cascade willprobably be most effective either within the first day aftertraining or after reactivation when reactivation leads toreconsolidation. However, as the effect of IGF-2 on corticalregions still needs to be determined, it is possible thatmemory-enhancing effects in the cortex may have differenttemporal evolutions.
Concluding remarksImportant questions arise concerning memory enhance-ment that targets consolidation and reconsolidation mech-anisms (Box 1). First, are the enhancing effects selectivefor the active trace and, therefore, only affect an activememory? This would restrict their effect, eliminatingthem as treatments that might globally enhance all storedmemories. However, these types of pharmacological treat-ment could perhaps be paired with brain stimulation,which would activate the memory traces, allowing themto respond to the treatment. Second, from the resultsobtained, one can infer that if consolidation or reconsoli-dation is impaired by, for example, neurodegenerativedisease, memory enhancers may be ineffective. Thus, itis important that memory enhancers are tested and in-vestigated in disease models at multiple stages of diseaseprogression. Memory enhancers targeting consolidation
Box 1. Outstanding questions
� What are the mechanisms of action of memory enhancers?
Memory enhancers may provide substrates that cooperate with
encoding, synaptic/system consolidation and/or memory retrieval
mechanisms and either prolong and/or potentiate these processes, or
oppose negative constraints. An example is hippocampally adminis-
tered IGF-2 that acts only if present during active phases of the
memory, either post-training or post-retrieval [26]. Other examples
probably include changing the neurotransmitter or glutamate
receptor-mediated responses [113] and the general state of chroma-
tin to promote the expression of genes [114] or cell excitability
[23,115] that mediate synaptic plasticity to promote memory forma-
tion or persistence. It would also be interesting to determine whether/
which mechanisms have universal or selective effects in different
brain regions, memory systems, memory tasks and/or memory trace.
Alternatively, memory enhancers may target the basal state of the
system and prolong memory storage, as in the case of enhanced
expression of PKMz [116,117]. With this approach, memories could
be, in principle, enhanced at any time after their formation and the
effect should be unselective, therefore targeting all stored memories.
� Memory enhancers as potential treatments in diseases of memory
decay: will they help? How? Little is known about whether or how
memory enhancers can be used as effective treatments in memory
decay disorders, including aging-related memory loss and AD.
Although animal model studies suggest that some compounds that
produce memory enhancement also prevent memory loss in
models of AD [73], it needs to be determined whether the effect
on the memory is long lasting. Importantly, it also needs to be
determined whether the compounds enhance the abilities of the
system (and whatever remains of it) or actually rescue or bypass
defective mechanisms. If the compound reverses the deficits, an
early intervention may significantly prevent the progression of the
disease and may be the best or only successful intervention.
� Memory enhancers: are they producing enhanced memory but
inflexible behavior? Overlapping memories and memory systems
exist and little, if anything, is known about whether enhancement of
certain memories comes at the expense of the retention of other
memories already formed, or of modifying/updating memories, or,
finally, at the potentials of encoding new memories. In other words,
as in LTP [118,119], does a memory potentiation occlude the system
or make the system less flexible?
� What aspect of memory is enhanced? Behavioral studies need to
dissect whether memory enhancers affect the general representa-
tion of memory, thereby enhancing it as a whole, or whether
selected components of the memory are affected (e.g. emotion,
spatial, perception, execution, etc.).
� Enhancing memory in normal subjects: ethical problems. It is
important to mention briefly that ethical issues should be discussed
and ethics committees should provide guidelines about the use of
memory enhancers, according to the effects found [120]. For
example, enhancing memories may change emotional aspects of
the memory that can cause affect dysregulation (e.g. enhancing
painful, stressful and/or traumatic memories). Thus, studies are
required to understand carefully the mechanisms and both the
positive and negative consequences of enhancing memories.
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
and reconsolidation may hopefully be able to compensatefor, or rescue, defects that may well be the cause of thedisease, thus significantly slowing the progression of thedisorder. In other words, prevention would be the most, orperhaps the only, successful strategy. Third, as memory-enhancing treatments would be needed for non-aversivememories, the consolidation and reconsolidation mecha-nisms of appetitive or problem-solving memories will haveto be better investigated and understood. Finally, a safe andclinically applicable memory enhancer would also need to behighly specific and have minimal adverse effects. Impor-tantly, studies on memory enhancement should examinemore carefully the effect of treatment on multiple tasks andbrain functions to assess whether memory enhancementcompromises the flexibility of memory or brain plasticity.Given that memory formation is such a dynamic process,gaining a more complete understanding of the anatomicaland temporal dynamics of the molecular and systemschanges required after learning and retrieval to consolidatememories will enable researchers to develop the most spe-cific and efficacious memory enhancers.
AcknowledgmentsWe dedicate this review to Rusiko Bourtchouladze, who passed away onAugust 6, 2011. She was a pioneer of the work on the role of CREB inmemory, an outstanding scientist and a wonderful friend. The writing ofthis review, and part of the work described within, were supported by theNational Institute of Mental Health (R01-MH065635 and R01-MH074736to C.M.A. and F31-MH816213 and T32-GM007280 to D.Y.C.).
References1 Meek, P.D. et al. (1998) Economic considerations in Alzheimer’s disease.
Pharmacotherapy 18, 68–73 discussion 79-82.2 Lynch, G. et al. (2011) The likelihood of cognitive enhancement.
Pharmacol. Biochem. Behav. 99, 116–129
3 Roesler, R. and Schroder, N. (2011) Cognitive enhancers: focus onmodulatory signaling influencing memory consolidation. Pharmacol.Biochem. Behav. 99, 155–163
4 Wallace, T.L. et al. (2011) Drug targets for cognitive enhancementin neuropsychiatric disorders. Pharmacol. Biochem. Behav. 99,130–145
5 McGaugh, J.L. and Roozendaal, B. (2002) Role of adrenal stresshormones in forming lasting memories in the brain. Curr. Opin.Neurobiol. 12, 205–210
6 McGaugh, J.L. and Roozendaal, B. (2009) Drug enhancement of memoryconsolidation: historical perspective and neurobiological implications.Psychopharmacology 202, 3–14
7 Korol, D.L. (2002) Enhancing cognitive function across the life span.Ann. N. Y. Acad. Sci. 959, 167–179
8 Smith, M.A. et al. (2011) Glucose enhancement of human memory: acomprehensive research review of the glucose memory facilitation effect.Neurosci. Biobehav. Rev. 35, 770–783
9 McGaugh, J.L. (2000) Memory – a century of consolidation. Science 287,248–251
10 Alberini, C.M. (2008) The role of protein synthesis during the labilephases of memory: revisiting the skepticism. Neurobiol. Learn. Mem.89, 234–246
11 Alberini, C.M. et al. (2012) Memory consolidation and its underlyingmechanisms. In Memory Mechanisms in Health and Disease:Mechanistic Basis of Memory (Giese, K.P., ed.), World ScientificPublishing.
12 Dudai, Y. (2006) Reconsolidation: the advantage of being refocused.Curr. Opin. Neurobiol. 16, 174–178
13 Nader, K. et al. (2000) Fear memories require protein synthesisin the amygdala for reconsolidation after retrieval. Nature 406, 722–726
14 Sara, S.J. (2000) Retrieval and reconsolidation: toward a neurobiologyof remembering. Learn. Mem. 7, 73–84
15 Alberini, C.M. (2011) The role of reconsolidation and the dynamicprocess of long-term memory formation and storage. Front. Behav.Neurosci. 5, 12
16 Eisenberg, M. and Dudai, Y. (2004) Reconsolidation of fresh, remote,and extinguished fear memory in Medaka: old fears don’t die. Eur. J.Neurosci. 20, 3397–3403
17 Frankland, P.W. et al. (2006) Stability of recent and remote contextualfear memory. Learn. Mem. 13, 451–457
281
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
18 Milekic, M.H. and Alberini, C.M. (2002) Temporally gradedrequirement for protein synthesis following memory reactivation.Neuron 36, 521–525
19 Suzuki, A. et al. (2004) Memory reconsolidation and extinctionhave distinct temporal and biochemical signatures. J. Neurosci. 24,4787–4795
20 Litvin, O.O. and Anokhin, K.V. (2000) Mechanisms of memoryreorganization during retrieval of acquired behavioral experience inchicks: the effects of protein synthesis inhibition in the brain. Neurosci.Behav. Physiol. 30, 671–678
21 Dudai, Y. and Eisenberg, M. (2004) Rites of passage of the engram:reconsolidation and the lingering consolidation hypothesis. Neuron 44,93–100
22 Inda, M.C. et al. (2011) Memory retrieval and the passage of time: fromreconsolidation and strengthening to extinction. J. Neurosci. 31, 1635–1643
23 Lee, Y.S. and Silva, A.J. (2009) The molecular and cellular biology ofenhanced cognition. Nat. Rev. Neurosci. 10, 126–140
24 Tsien, J.Z. (2000) Building a brainier mouse. Sci. Am. 282, 62–6825 Alberini, C.M. (2009) Transcription factors in long-term memory and
synaptic plasticity. Physiol. Rev. 89, 121–14526 Chen, D.Y. et al. (2011) A critical role for IGF-II in memory
consolidation and enhancement. Nature 469, 491–49727 Alberini, C.M. et al. (1994) C/EBP is an immediate-early gene required
for the consolidation of long-term facilitation in Aplysia. Cell 76, 1099–1114
28 Bartsch, D. et al. (1998) CREB1 encodes a nuclear activator, arepressor, and a cytoplasmic modulator that form a regulatory unitcritical for long-term facilitation. Cell 95, 211–223
29 Tully, T. et al. (1994) Genetic dissection of consolidated memory inDrosophila. Cell 79, 35–47
30 Dudai, Y. (2002) Molecular bases of long-term memories: a question ofpersistence. Curr. Opin. Neurobiol. 12, 211–216
31 Squire, L.R. et al. (2001) Retrograde amnesia. Hippocampus 11, 50–5532 Kandel, E.R. (2001) The molecular biology of memory storage: a
dialogue between genes and synapses. Science 294, 1030–103833 Silva, A.J. et al. (1998) CREB and memory. Annu. Rev. Neurosci. 21,
127–14834 Dubnau, J. and Tully, T. (1998) Gene discovery in Drosophila:
new insights for learning and memory. Annu. Rev. Neurosci. 21,407–444
35 Balschun, D. et al. (2003) Does cAMP response element-binding proteinhave a pivotal role in hippocampal synaptic plasticity andhippocampus-dependent memory? J. Neurosci. 23, 6304–6314
36 Yin, J.C. et al. (1995) CREB as a memory modulator: inducedexpression of a dCREB2 activator isoform enhances long-termmemory in Drosophila. Cell 81, 107–115
37 Perazzona, B. et al. (2004) The role of cAMP response element-bindingprotein in Drosophila long-term memory. J. Neurosci. 24, 8823–8828
38 Lee, J.A. et al. (2001) Overexpression of and RNA interference with theCCAAT enhancer-binding protein on long-term facilitation of Aplysiasensory to motor synapses. Learn. Mem. 8, 220–226
39 Wang, H. et al. (2004) Overexpression of type-1 adenylyl cyclase inmouse forebrain enhances recognition memory and LTP. Nat.Neurosci. 7, 635–642
40 Jentsch, J.D. et al. (2002) Stimulation of protein kinase a activity in therat amygdala enhances reward-related learning. Biol. Psychiatry 52,111–118
41 Barad, M. et al. (1998) Rolipram, a type IV-specific phosphodiesteraseinhibitor, facilitates the establishment of long-lasting long-termpotentiation and improves memory. Proc. Natl. Acad. Sci. U.S.A. 95,15020–15025
42 Rutten, K. et al. (2006) Rolipram reverses scopolamine-induced andtime-dependent memory deficits in object recognition by differentmechanisms of action. Neurobiol. Learn. Mem. 85, 132–138
43 Reneerkens, O.A. et al. (2009) Selective phosphodiesterase inhibitors: apromising target for cognition enhancement. Psychopharmacology 202,419–443
44 Li, Y.F. et al. (2011) Phosphodiesterase-4D knock-out and RNAinterference-mediated knock-down enhance memory and increasehippocampal neurogenesis via increased cAMP signaling. J. Neurosci.31, 172–183
282
45 Prickaerts, J. et al. (2005) Dissociable effects of acetylcholinesteraseinhibitors and phosphodiesterase type 5 inhibitors on objectrecognition memory: acquisition versus consolidation.Psychopharmacology 177, 381–390
46 Rutten, K. et al. (2005) The selective PDE5 inhibitor, sildenafil,improves object memory in Swiss mice and increases cGMP levels inhippocampal slices. Behav. Brain. Res. 164, 11–16
47 Shafiei, M. et al. (2006) Effect of sildenafil (Viagra) on memoryretention of a passive avoidance response in rats. Acta Physiol.Hung. 93, 53–59
48 Josselyn, S.A. et al. (2001) Long-term memory is facilitated by cAMPresponse element-binding protein overexpression in the amygdala. J.Neurosci. 21, 2404–2412
49 Restivo, L. et al. (2009) Viral-mediated expression of a constitutivelyactive form of CREB in hippocampal neurons increases memory.Hippocampus 19, 228–234
50 Suzuki, A. et al. (2011) Upregulation of CREB-mediated transcriptionenhances both short- and long-term memory. J. Neurosci. 31,8786–8802
51 Han, J.H. et al. (2007) Neuronal competition and selection duringmemory formation. Science 316, 457–460
52 Han, J.H. et al. (2009) Selective erasure of a fear memory. Science 323,1492–1496
53 Zhou, Y. et al. (2009) CREB regulates excitability and the allocation ofmemory to subsets of neurons in the amygdala. Nat. Neurosci. 12,1438–1443
54 Lopez de Armentia, M. et al. (2007) cAMP response element-bindingprotein-mediated gene expression increases the intrinsic excitability ofCA1 pyramidal neurons. J. Neurosci. 27, 13909–13918
55 Abel, T. et al. (1998) Memory suppressor genes: inhibitory constraintson the storage of long-term memory. Science 279, 338–341
56 Bartsch, D. et al. (1995) Aplysia CREB2 represses long-termfacilitation: relief of repression converts transient facilitation intolong-term functional and structural change. Cell 83, 979–992
57 Chen, A. et al. (2003) Inducible enhancement of memory storage andsynaptic plasticity in transgenic mice expressing an inhibitor of ATF4(CREB-2) and C/EBP proteins. Neuron 39, 655–669
58 Yin, J.C. et al. (1994) Induction of a dominant negative CREBtransgene specifically blocks long-term memory in Drosophila. Cell79, 49–58
59 Costa-Mattioli, M. et al. (2005) Translational control of hippocampalsynaptic plasticity and memory by the eIF2alpha kinase GCN2. Nature436, 1166–1173
60 Costa-Mattioli, M. et al. (2007) eIF2alpha phosphorylationbidirectionally regulates the switch from short- to long-termsynaptic plasticity and memory. Cell 129, 195–206
61 Kouzarides, T. (2007) Chromatin modifications and their function. Cell128, 693–705
62 Barrett, R.M. and Wood, M.A. (2008) Beyond transcription factors: therole of chromatin modifying enzymes in regulating transcriptionrequired for memory. Learn. Mem. 15, 460–467
63 Petrij, F. et al. (1995) Rubinstein-Taybi syndrome caused by mutationsin the transcriptional co-activator CBP. Nature 376, 348–351
64 Oike, Y. et al. (1999) Truncated CBP protein leads to classicalRubinstein-Taybi syndrome phenotypes in mice: implications for adominant-negative mechanism. Hum. Mol. Genet. 8, 387–396
65 Korzus, E. et al. (2004) CBP histone acetyltransferase activity is acritical component of memory consolidation. Neuron 42, 961–972
66 Alarcon, J.M. et al. (2004) Chromatin acetylation, memory, and LTPare impaired in CBP+/� mice: a model for the cognitive deficit inRubinstein-Taybi syndrome and its amelioration. Neuron 42, 947–959
67 Bourtchouladze, R. et al. (2003) A mouse model of Rubinstein-Taybisyndrome: defective long-term memory is ameliorated by inhibitors ofphosphodiesterase 4. Proc. Natl. Acad. Sci. U.S.A. 100, 10518–10522
68 Levenson, J.M. et al. (2004) Regulation of histone acetylation duringmemory formation in the hippocampus. J. Biol. Chem. 279, 40545–40559
69 Fischer, A. et al. (2007) Recovery of learning and memory is associatedwith chromatin remodelling. Nature 447, 178–182
70 Yeh, S.H. et al. (2004) Acetylation of nuclear factor-kappaB in ratamygdala improves long-term but not short-term retention of fearmemory. Mol. Pharmacol. 65, 1286–1292
Review Trends in Neurosciences May 2012, Vol. 35, No. 5
71 Bredy, T.W. et al. (2007) Histone modifications around individualBDNF gene promoters in prefrontal cortex are associated withextinction of conditioned fear. Learn. Mem. 14, 268–276
72 Stefanko, D.P. et al. (2009) Modulation of long-term memory for objectrecognition via HDAC inhibition. Proc. Natl. Acad. Sci. U.S.A. 106,9447–9452
73 Chuang, D.M. et al. (2009) Multiple roles of HDAC inhibition inneurodegenerative conditions. Trends Neurosci. 32, 591–601
74 Abel, T. and Zukin, R.S. (2008) Epigenetic targets of HDAC inhibitionin neurodegenerative and psychiatric disorders. Curr. Opin.Pharmacol. 8, 57–64
75 Fischer, A. et al. (2010) Targeting the correct HDAC(s) to treatcognitive disorders. Trends Pharmacol. Sci. 31, 605–617
76 Russo, V.C. et al. (2005) The insulin-like growth factor system and itspleiotropic functions in brain. Endocr. Rev. 26, 916–943
77 Rotwein, P. et al. (1988) Differential expression of insulin-like growthfactor genes in rat central nervous system. Proc. Natl. Acad. Sci.U.S.A. 85, 265–269
78 Brown, J. et al. (2009) Keeping IGF-II under control: lessonsfrom the IGF-II-IGF2R crystal structure. Trends Biochem. Sci. 34,612–619
79 Ghosh, P. et al. (2003) Mannose 6-phosphate receptors: new twists inthe tale. Nat. Rev. Mol. Cell. Biol. 4, 202–212
80 Braulke, T. and Bonifacino, J.S. (2009) Sorting of lysosomal proteins.Biochim. Biophys. Acta 1793, 605–614
81 Shamblott, M.J. et al. (1998) Characterization of a teleost insulin-likegrowth factor II (IGF-II) gene: evidence for promoter CCAAT/enhancer-binding protein (C/EBP) sites, and the presence ofhepatic C/EBP. Mol. Mar. Biol. Biotechnol. 7, 181–190
82 Agis-Balboa, R.C. et al. (2011) A hippocampal insulin-growth factor 2pathway regulates the extinction of fear memories. EMBO J. 30,4071–4083
83 Murphy, L.J. et al. (1987) Tissue distribution of insulin-like growthfactor I and II messenger ribonucleic acid in the adult rat.Endocrinology 120, 1279–1282
84 Pardridge, W.M. (1993) Transport of insulin-related peptides andglucose across the blood–brain barrier. Ann. N. Y. Acad. Sci. 692,126–137
85 Hawkes, C. and Kar, S. (2004) The insulin-like growth factor-II/mannose-6-phosphate receptor: structure, distribution and functionin the central nervous system. Brain Res. Brain Res. Rev. 44, 117–140
86 Guzowski, J.F. et al. (2000) Inhibition of activity-dependent arcprotein expression in the rat hippocampus impairs themaintenance of long-term potentiation and the consolidation oflong-term memory. J. Neurosci. 20, 3993–4001
87 Ploski, J.E. et al. (2008) The activity-regulated cytoskeletal-associatedprotein (Arc/Arg3.1) is required for memory consolidation of pavlovianfear conditioning in the lateral amygdala. J. Neurosci. 28, 12383–12395
88 Bramham, C.R. et al. (2008) The immediate early gene arc/arg3.1:regulation, mechanisms, and function. J. Neurosci. 28, 11760–11767
89 Chowdhury, S. et al. (2006) Arc/Arg3.1 interacts with the endocyticmachinery to regulate AMPA receptor trafficking. Neuron 52,445–459
90 Choquet, D. (2010) Fast AMPAR trafficking for a high-frequencysynaptic transmission. Eur. J. Neurosci. 32, 250–260
91 Malinow, R. and Malenka, R.C. (2002) AMPA receptor trafficking andsynaptic plasticity. Annu. Rev. Neurosci. 25, 103–126
92 Smillie, K.J. and Cousin, M.A. (2011) The role of GSK3 in presynapticfunction. Int. J. Alzheimers Dis. DOI: 10.4061/2011/263673
93 Clayton, E.L. et al. (2010) Dynamin I phosphorylation by GSK3controls activity-dependent bulk endocytosis of synaptic vesicles.Nat. Neurosci. 13, 845–851
94 Gregg, C. et al. (2010) Sex-specific parent-of-origin allelic expressionin the mouse brain. Science 329, 682–685
95 Gregg, C. et al. (2010) High-resolution analysis of parent-of-originallelic expression in the mouse brain. Science 329, 643–648
96 Wilkinson, L.S. et al. (2007) Genomic imprinting effects on braindevelopment and function. Nat. Rev. Neurosci. 8, 832–843
97 Babri, S. et al. (2007) Intrahippocampal insulin improves memory in apassive-avoidance task in male wistar rats. Brain Cogn. 64, 86–91
98 Craft, S. et al. (1999) Enhancement of memory in Alzheimer diseasewith insulin and somatostatin, but not glucose. Arch. Gen. Psychiatry56, 1135–1140
99 Irvine, E.E. et al. (2011) Insulin receptor substrate 2 is a negativeregulator of memory formation. Learn. Mem. 18, 375–383
100 Alberini, C.M. (2005) Mechanisms of memory stabilization: areconsolidation and reconsolidation similar or distinct processes?Trends Neurosci. 28, 51–56
101 Milekic, M.H. et al. (2007) Temporal requirement of C/EBPbeta in theamygdala following reactivation but not acquisition of inhibitoryavoidance. Learn. Mem. 14, 504–511
102 Debiec, J. et al. (2002) Cellular and systems reconsolidation in thehippocampus. Neuron 36, 527–538
103 Wang, S.H. et al. (2009) Cellular and systems mechanisms of memorystrength as a constraint on auditory fear reconsolidation. Nat.Neurosci. 12, 905–912
104 Taubenfeld, S.M. et al. (2001) The consolidation of new but notreactivated memory requires hippocampal C/EBPbeta. Nat.Neurosci. 4, 813–818
105 Lee, J.L. (2008) Memory reconsolidation mediates the strengtheningof memories by additional learning. Nat. Neurosci. 11, 1264–1266
106 Tronson, N.C. et al. (2006) Bidirectional behavioral plasticity ofmemory reconsolidation depends on amygdalar protein kinase A.Nat. Neurosci. 9, 167–169
107 Frenkel, L. et al. (2005) Memory strengthening by a real-life episodeduring reconsolidation: an outcome of water deprivation via brainangiotensin II. Eur. J. Neurosci. 22, 1757–1766
108 Eckel-Mahan, K.L. and Storm, D.R. (2006) Rookie snail protein LAPSveteran C/EBP: net transcriptional proceeds for long-termfacilitation. Neuron 49, 645–646
109 Belfiore, A. et al. (2009) Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease.Endocr. Rev. 30, 586–623
110 Sachdev, D. and Yee, D. (2007) Disrupting insulin-like growth factorsignaling as a potential cancer therapy. Mol. Cancer Ther. 6, 1–12
111 Morcavallo, A. et al. (2011) Research resource: new and diversesubstrates for the insulin receptor isoform A revealed byquantitative proteomics after stimulation with IGF-II or insulin.Mol. Endocrinol. 25, 1456–1468
112 Shepherd, J.D. and Huganir, R.L. (2007) The cell biology of synapticplasticity: AMPA receptor trafficking. Annu. Rev. Cell. Dev. Biol. 23,613–643
113 Floresco, S.B. and Jentsch, J.D. (2011) Pharmacological enhancementof memory and executive functioning in laboratory animals.Neuropsychopharmacology 36, 227–250
114 Guan, J.S. et al. (2009) HDAC2 negatively regulates memoryformation and synaptic plasticity. Nature 459, 55–60
115 Murphy, G.G. et al. (2004) Increased neuronal excitability, synapticplasticity, and learning in aged Kvbeta1.1 knockout mice. Curr. Biol.14, 1907–1915
116 Drier, E.A. et al. (2002) Memory enhancement and formation byatypical PKM activity in Drosophila melanogaster. Nat. Neurosci.5, 316–324
117 Shema, R. et al. (2009) Boundary conditions for the maintenance ofmemory by PKMzeta in neocortex. Learn. Mem. 16, 122–128
118 Sacchetti, B. et al. (2002) Time-dependent inhibition of hippocampalLTP in vitro following contextual fear conditioning in the rat. Eur. J.Neurosci. 15, 143–150
119 Schroeder, B.W. and Shinnick-Gallagher, P. (2005) Fear learninginduces persistent facilitation of amygdala synaptic transmission.Eur. J. Neurosci. 22, 1775–1783
120 Erler, A. (2011) Does memory modification threaten our authenticity?Neuroethics 4, 235–249
283